Physician profile
Ashley E Clark
NPI 1871956300
$5,486.14
in general payments reported to CMS, 2019-2025
29 companies · $2,797 in 2025
The $2,797 reported for 2025 was more than what 82% of Pulmonary Disease providers received nationally (typical 2025 total: $500).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $12.80 · 2020: $12.37 · 2023: $736 · 2024: $1,929 · 2025: $2,797.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $5,444 · Education: $17.38.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $5,443.59 |
| Education | $17.38 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Astrazeneca Pharmaceuticals LP | $972.53 | 2023-2025 | Airsupra, Fasenra, Tezspire |
| Merck Sharp & Dohme LLC | $554.39 | 2023-2025 | Winrevair, Keytruda, Capvaxive |
| Boehringer Ingelheim Pharmaceuticals, INC. | $484.63 | 2023-2025 | Ofev, Spiriva Respimat, Jascayd |
| Actelion Pharmaceuticals US, INC. | $465.32 | 2023-2025 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $460.47 | 2023-2025 | Dupixent |
| Genzyme Corporation | $405.68 | 2023-2025 | |
| Glaxosmithkline, LLC. | $347.73 | 2024-2025 | Nucala, Trelegy Ellipta, Arexvy |
| Insmed, INC. | $335.82 | 2023-2025 | Arikayce, Brinsupri |
| United Therapeutics Corporation | $268.87 | 2023-2025 | Tyvaso, Tyvaso |
| Grifols USA, LLC | $241.47 | 2023-2025 | Prolastin-C Liquid |
| Amgen INC. | $201.46 | 2023-2025 | Tezspire, Tavneos |
| Electromed, INC. | $133.39 | 2023-2025 | Smartvest |
| Viatris Specialty LLC | $105.42 | 2025 | Yupelri |
| Inspire Medical Systems, INC. | $83.94 | 2023-2025 | Inspire |
| Mylan Specialty L.P. | $67.95 | 2023-2024 | Yupelri |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Pfizer INC. | $52.00 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $39.47 | 2023-2024 | Xarelto |
| Verona Pharma, INC. | $31.45 | 2025 | Ohtuvayre |
| Vifor Pharma, INC. | $28.70 | 2025 | Zemaira |
| Alkermes, INC. | $25.96 | 2025 | Vivitrol |
| Ani Pharmaceuticals, INC. | $23.58 | 2024 | Purified Cortrophin Gel |
| Abbvie INC. | $23.41 | 2025 | |
| Axsome Therapeutics, INC. | $23.17 | 2024 | Sunosi |
| Lilly USA, LLC | $21.77 | 2025 | Zepbound |
| 3b Medical, INC. | $21.34 | 2025 | Luna |
| Azurity Pharmaceuticals, INC. | $19.38 | 2025 | Alvesco |
| Bayer Healthcare Pharmaceuticals INC. | $18.58 | 2025 | |
| Novartis Pharmaceuticals Corporation | $15.89 | 2025 | |
| Veran Medical Technologies, INC. | $12.37 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Ashley Clark listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.